Related Experiment Video

Updated: May 8, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Noninvasive assessment of liver damage in chronic hepatitis B

Mehmet Celikbilek1, Serkan Dogan, Sebnem Gursoy

  • 1Mehmet Celikbilek, Department of Gastroenterology, Medical School, Bozok University, 66200 Yozgat, Turkey.

World Journal of Hepatology
|September 12, 2013
PubMed

Insights

The neutrophil-lymphocyte ratio correlates with liver damage activity in chronic hepatitis B (CHB). The aspartate aminotransferase/platelet ratio index (APRI) may help rule out cirrhosis in CHB patients.

Area of Science:

  • Hepatology
  • Biomarkers
  • Diagnostic Accuracy

Background:

  • Chronic hepatitis B (CHB) poses a significant global health challenge.
  • Accurate prediction of liver damage, including fibrosis and cirrhosis, is crucial for CHB management.
  • Non-invasive markers are sought to complement liver biopsy assessments.

Purpose of the Study:

  • To assess the efficacy of the aspartate aminotransferase/platelet ratio index (APRI) and neutrophil-lymphocyte (N/L) ratio in predicting liver damage in CHB patients.
  • To correlate these markers with histological findings from liver biopsies.

Main Methods:

  • Analysis of 89 CHB patients and 43 healthy controls.
  • Liver biopsy assessment using Ishak scoring for fibrosis and histological activity index (HAI).
  • Calculation of APRI and N/L ratios from blood test results.

Main Results:

  • APRI scores were significantly higher in CHB patients compared to controls (P < 0.001).
  • N/L ratios did not differ significantly between CHB patients and controls.
  • N/L ratio showed a significant negative correlation with HAI (r = -0.218, P = 0.041).
  • APRI score demonstrated potential in identifying cirrhosis, with an optimal cut-off of 1.01.

Conclusions:

  • The neutrophil-lymphocyte ratio is negatively correlated with liver disease activity (HAI) in CHB.
  • The APRI score may be a useful tool for excluding cirrhosis in CHB patients, particularly with a cut-off of 1.01.
Abstract

Keywords:
Chronic hepatitis BFibrosisLiver cirrhosisNoninvasiveSerum markers

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...